Tarsus Pharmaceuticals, Inc. (TARS) Misses Q2 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts TARS Hot Sheet
Join SI Premium – FREE
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q2 EPS of ($0.48), $0.10 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $102.7 million versus the consensus estimate of $95.68 million.
For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tarsus Pharmaceuticals (TARS) PT Raised to $106 at H.C. Wainwright
- Flutter Entertainment (FLUT) PT Lowered to $160 at Jefferies
- Tarsus Pharmaceuticals (TARS) PT Raised to $103 at Oppenheimer
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
